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Background: Cystic fibrosis (CF) is the most common inherited disorder in Caucasian populations, with more than 1000 cystic fibrosis
transmembrane conductance regulator (CFTR) mutations presently described. The distribution of the mutations ranges widely between
countries and/or ethnic groups. Multicentric studies are usually needed to study the genotype–phenotype correlations.
Methods: Since 1992, the French CF Registry (FCFR) has collected and analyzed data from most of the CF patients regularly seen in CF
care centres in France. We compared the mutation distribution of the patients born in western France to that of those born elsewhere in
France. Then we extracted the available data for all the compound heterozygotes carrying the DF508 allele and one of the following
mutations: DI507, 1078delT, 4005+1G-NA, E60X and W846X, and matched a patient homozygous for the DF508 mutation for each of them.
Results: Western France appeared to have a specific distribution of some CF mutations. Furthermore, disparities were found regarding the
mutation repartition (DI507 in Normandy, 1078delT, 4005+1G-NA and W846X in western Brittany). Genotype–phenotype correlations
showed a wide heterogeneity. Although variations were found, DI507/DF508, 4005+1G-NA/DF508 and 1078delT/DF508 patients appeared
to have a similar disease as the DF508/DF508 patients. Although the W846X and E60X mutations should be considered as severe alleles as
regards to pancreatic function, they were associated with less severe pulmonary manifestations and, probably, better prognosis.
Conclusion: The knowledge of the distribution of uncommon CF mutations specific to particular areas and of their associated phenotype
makes up an essential tool in the management of local CF patients.
D 2004 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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Cystic fibrosis (CF) is the most common inherited
disorder in Caucasian populations. It is characterized by a
chronicle and progressive obstructive lung disease, pancre-
atic insufficiency and high sweat electrolyte levels. Despite
being a monogenic disease, cystic fibrosis (CF) appears to be1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
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* Corresponding author. Laboratoire d’Histologie, Embryologie et
Cytoge´ne´tique, Faculte´ de Me´decine et des Sciences de la Sante´, Universite´
de Bretagne Occidentale, Brest, France. Tel.: +33 2 98 01 64 76; fax: +33 2
98 01 81 89.
E-mail address: marc.debraekeleer@univ-brest.fr (M. De Braekeleer).very heterogeneous. Indeed, since the cystic fibrosis trans-
membrane conductance regulator (CFTR) gene was cloned
in 1989, more than 1000 mutations have been described
(http://genet.sickkids.on.ca/cftr) [1–3].
The distribution of those CFTR mutations ranges widely
between countries and/or ethnic groups. Several authors
already showed that some mutations rarely described
elsewhere have a high frequency in western France [4–9].
This region, which includes Brittany, Normandy and Pays-
de-Loire, accounts for 15% of the French population (about
9.5 millions inhabitants) on one-sixth of the metropolitan
territory.
Several attempts have been made to correlate the
phenotype with the genotype among patients sharing the3 (2004) 259–263ed by Elsevier B.V. All rights reserved.
Table 1
Distribution of the CF alleles in western France and in the other French
regions
Western France Other regions
Number
of alleles
Frequency
(%)
Number
of alleles
Frequency
(%)
DI507 16 0.97 36 0.55
1078delT 33 2.00 12 0.18
4005+1G-NA 6 0.36 13 0.20
E60X 7 0.43 3 0.05
W846X 9 0.55 7 0.11
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mutations have a low frequency, multicentric studies are
needed to investigate their relationship with the CF
phenotype. The French CF Registry (FCFR), which
performs annually an enquiry on the patients followed in
the CF centres, offers such an opportunity [14].
This study reports the distribution of five mutations that
are apparently more frequent in western France and the
results of a genotype–phenotype correlation analysis for
those mutations.
DF508 1118 68.00 4031 61.22
Other mutations 306 18.61 1376 20.90
Unknown mutations 149 9.06 1106 16.80
Total 1644 6584
2. Materials and methods
Since 1992, the French CF Registry has collected and
analyzed data from most of the CF patients regularly seen in
CF care centres in France. It is based on a yearly
questionnaire, collecting demographic, clinical and social
data for every CF patient seen during that period.
In a first step, we extracted the genotypic data on all the
CF patients who attended in a participating care centre in
2000, separating the patients born in one of the three French
administrative areas of Brittany, Normandy or Pays-de-
Loire constituting western France, from those born else-
where in France.
In a second step, we extracted the available data for all
the compound heterozygotes carrying the DF508 allele and
one of the following mutations: DI507, 1078delT,
4005+1G-NA, E60X and W846X, as previously described
[15]. Each patient was matched to a patient homozygous for
the DF508 mutation of same sex and age (F1 year old),
having consulted in the same CF care centre. All the data
were obtained from the 2000 enquiry, except for clinical
events that were compiled during the last 7 years (1994–
2000).
Categorical variables were compared using the Chi-
square test or, for small size samples, the Fisher’s Exact
Test. Continuous variables were compared by a Student’s
t-test. A significant level of 5% was used. Analyses were
performed using Epi Info 6.04 FR.3. Results
Table 1 shows the geographic distribution of the five
CFTR mutations under study. Overall, 8258 CF chromo-
somes have been analyzed. The DF508 allele was identified
on 68% of the CF chromosomes from western France,
compared to 61% in the other French regions ( pb0.0001).
Five CFTR mutations (DI507, 4005+1G-NA, 1078delT,
E60X and W846X) were more commonly identified in
western France than in the other regions ( pb0.05 for all but
one alleles). The frequency of the 4005+1G-NA mutation
was not significantly different between western and non-
western regions ( p=0.16). However, within western France,
this mutation was restricted to Brittany, its frequency beingsignificantly different from the rest of the western region
( p=0.0049) and France ( p=0.0032; Table 2).
All patients compound heterozygous for one of these five
mutations and the DF508 allele were compared to matched
DF508 homozygotes (Table 3). The data pertaining to the
five DF508 homozygotes groups is not shown.
Twenty-one DI507/DF508 patients were included in the
present study (Table 3). Mean age at diagnostic was higher
than for the DF508 homozygotes (21.6 versus 12.6 months).
Five patients from both groups had meconium ileus. Growth
retardation at diagnosis was less frequent in the DI507/
DF508 group than in the DF508/DF508 group (3 versus 9,
p=0.042). Although the DI507/DF508 patients had better
weight Z scores, better BMI, FVC and FEV1 than the
DF508 homozygous patients, the values were not signifi-
cantly different. All patients were pancreatic-insufficient. A
DF508/DF508 female died during the study at the age of
16.3 years old because of respiratory failure.
Ten 4005+1G-NA/DF508 patients were compared to 10
matched DF508 homozygous patients (Table 3). The mean
age at diagnosis was higher but not significantly different in
the compound heterozygous group than in the DF508
homozygous group. However, this may explain, at least in
part, why one half of the 4005+1G-NA/DF508 patients had
respiratory symptoms at diagnosis compared to one third of
the DF508/DF508 patients. No statistical significance was
found between the several variables analyzed but for the
presence of Staphylococcus aureus resistant to meticillin
( p=0.02) and Candida ( p=0.03). All 4005+1G-NA/DF508
patients had pancreatic insufficiency.
Twenty-three 1078delT/DF508 patients were also studied
(Table 3). Although not significant, the mean age at
diagnosis was lower among the 1078delT/DF508 patients
than the DF508 homozygous patients. This could be
explained, at least in part, by a higher rate of meconium
ileus among the compound heterozygotes (5 versus 1,
p=0.07). 1078delT/DF508 patients had lower mean height
and weight Z scores ( p=0.06 and p=0.09, respectively). A
higher proportion of them had liver cirrhosis (6/22 versus 1/
22, p=0.04). All compound heterozygotes for the 1078delT
were pancreatic-insufficient.
Table 2
Distribution of the five CFTR alleles in the three regions of western France
DI507 1078delT 4005+1G-NA E60X W846X
Brittany 6(37.5%) 28(84.8%) 6(100.0%) 5(71.3%) 5(55.5%)
Normandy 8(50.0%) 2(6.1%) 0 2(28.7%) 3(33.3%)
Pays-de-Loire 2(12.5%) 3(9.1%) 0 0 1(11.2%)
Western France 16(100.0%) 33(100.0%) 6(100.0%) 7(100.0%) 9(100.0%)
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were included in the present study (Table 3). The mean
age at diagnosis was higher in the former than in the
latter group (58.1 versus 15.0 months); however, the
difference was not statistically significant. The mean
height and weight Z scores were higher among the
E60X/DF508 patients but not statistically different from
those of DF508 homozygous patients. Nevertheless, theTable 3
Clinical and laboratory findings of the CF patients distributed in the five genotyp
DI507/DF508 4005+
Sex (males/females) 10/11 4/6
Age on Jan 1, 2001
(years)*
Mean age onFS.D. 12.3F6.7 12.8F
Median age 11.00 8.50
Age group [0–14] 14 7
Age group [15–29] 7 3
Age group [30 and over] 0 0
Age at diagnosis
(months)**
Mean ageFS.D. 21.6F23.1 38.0F
Median age 9.00 11.5
Sweat chloride
concentration (mEq/l)
Mean valueFS.D. 110.6F29.6(15) 97.0F
Median value 102.00 98.00
Status at diagnosis
(number of patients)
Family history, prenatal
diagnosis, neonatal
screening
6/21 2/10
Meconium ileus 5/21 2/10
Malnutrition 3/21( p=0.042) 2/10
Diarrhoea 8/21 3/10
Respiratory symptoms 5/21 5/10
Anthropometry* Height (Z score)FS.D. 0.245F0.980(20) 0.01
Weight (Z score)FS.D. 0.360F1.496(20) 0.21
BMIFS.D. 16.96F1.98(20) 16.66
Pulmonary status* (%
of predicted values)
FEV1FS.D. 80.93F21.36(16) 84.49
FVCFS.D. 85.96F21.14(16) 91.91
Microbiology (number
of patients)
Haemophilus influenzae 6/20 6/10
Staphilococcus aureus 9/20 6/10
Staphilococcus aureus
meticillin resistant
3/20 0/10(
Pseudomonas
aeruginosa
4/20 6/10
Stenotrophomonas
maltophilia
1/20 0/10
Burkholderia cepacia 0/20 0/10
Aspergillus 2/20 3/10
Candida 4/20 5/10(
Clinical events (number
of patients)
Liver cirrhosis 1/21 0/9
Diabetes mellitus 2/21 0/9
Pancreatitis 0/21 0/9
Intestinal obstruction 1/21 0/9
Nasal polyposis 2/21 2/9
Pancreatic insufficiency
(number of patients)
21/21 10/10
Numbers in parentheses—number of patients.
* Excluding patients who died during the study.
** Excluding positive family history, prenatal diagnosis and neonatal screenimean BMI value was significantly higher (19.1 versus 16.9,
p=0.05). The mean FEV1 and FCV values were much
higher among the E60X/DF508 patients but not signifi-
cantly different from those of the DF508 homozygotes.
Seven out of the nine E60X/DF508 patients had pancreatic
insufficiency.
Ten W846X/DF508 patients were included in the study
(Table 3). All of them had a G to A change at nucleotidee groups
1G-NA/DF508 1078delT/DF508 E60X/DF508 W846X/DF508
13/10 2/7 4/6
6.7 13.4F8.9 20.6F7.4 23.48F9.92
11.8 20.00 21.6
14 3 3
8 5 5
1 1 2
60.3 12.8F17.3 (13) 58.1F102.6 79.5F137.1
6.00 24.00 16.5
18.8(7) 108.8F33.8(19) 99.0F16.9(8) 126F26(4)
102.00 100.00 124
11/13 2/9 1/10
5/13( p=0.07) 1/9 0/10
6/13 0/9 3/10
7/13 2/9 6/10( p=0.0223)
5/13 4/9 4/10
2F1.412(8) 0.727F1.5(21) 0.462F0.88(8) 0.59F1.06(7)
2F1.764(8) 0.748F1.7(21) 0.438F1.196(8) 0.39F1.57(7)
F3.01(9) 17.4F2.7(21) 19.16F1.74(8) 0.05 19.27F3.87(7)
F33.73(7) 68.1F24.3(16) 70.74F23.57(7) 73.49F33.37(7)
F28.04(7) 81.9F18.7(16) 87.30F15.69(7) 80.86 28.05(7)
10/22 2/8 3/10
9/22 5/8 5/10
p=0.02) 3/22 2/8 0/10
7/22 4/8 5/10
1/22 0/8 0/10
0/22 1/8 0/10
4/22 3/8 3/10
p=0.03) 7/22 3/8 4/10
6/22( p=0.04) 1/7 0/10
1/22 0/7 1/10
1/22 0/7 0/10
0/22 1/7 1/10
2/22 1/7 4/10
23/23 7/9 10/10
ng.
I. Dugue´pe´roux, M. De Braekeleer / Journal of Cystic Fibrosis 3 (2004) 259–2632622670 (W846X2) and shared the same 16-32-13 micro-
satellite haplotype [16]. A wide variation in the age at
diagnosis was found, the mean age being 79.5 months
compared to 29 months among the DF508 homozygotes
( pN 0.05). More patients in the former group were
diagnosed because of diarrhoea (six versus one, p=0.02).
More DF508 homozygotes than W846X/DF508 patients
were colonized with Pseudomonas aeruginosa, the differ-
ence being borderline significant ( p=0.057). The mean
FEV1 and FCV values were much higher among the
W846X/DF508 patients but not significantly. All had
pancreatic insufficiency.
Three CF patients carrying one of the five genotypes
studied died between 1994 and 2000. One was W846X/
DF508, another DI507/DF508 and the last one E60X/DF508.4. Discussion
Only two of the five mutations studied (DI507 and
1078delT) are included among the 20 most common CF
mutations worldwide, with relative frequencies of 0.2% and
0.1%, respectively [17] (http://genet.sickkids.on.ca/cftr).
The E60X allele is also mentioned but as an uncommon
CF mutation in specific populations. Indeed, in Belgium, the
frequency of the E60X allele ranges from 1.0% to 2.1%
[18]. No data are found on the 4005+1G-NA and W846X
alleles in the CF database.
The detection rate of CF mutations is close to 100% in
western France. Indeed, it was 95.8% in Normandy, over
98% in western Brittany and 94% in Pays-de-Loire in 1994
[6,19]. Mittre et al. [8] established that the DI507 allele
represented 12.3% of the non-DF508 chromosomes and
4.2% of the CF chromosomes in the southern part of
Normandy, whereas it was only 0.6% in France. The authors
suggested the existence of a founder effect because all the
studied chromosomes carrying the DI507 allele were
associated with a single haplotype. The remaining four
mutations have a high frequency in Brittany. Scotet et al. [4]
reported a frequency over 3.5% for the 1078delT mutation,
0.8% for the 4005+1G-NA, 1.1% for the W846X and 0.7%
for the E60X. A founder effect was also postulated for the
1078delT and W846X mutations [16].
The DI507 mutation was first described by Kerem et al.
[21] in 1990 and is difficult to be distinguished from the
most common CFTR gene mutation (DF508) or from
DI506 [20,22]. Because of the genetic proximity of both
mutations, DI507 and DF508, and the high prevalence of
the latter one, the DI507 might have been under-identified
[23]. In 1991, Schwarz et al. [20] described a 12-year-old
boy with a DI507/DF508 genotype who had growth
retardation, pancreatic insufficiency, moderate pulmonary
disease, asthma and one P. aeruginosa positive sputum
culture.
No phenotype study of patients carrying a 4005+1G-NA/
DF508 genotype was found in the literature, which appearsto be as severe as the phenotype associated with a DF508/
DF508 genotype.
Although not statistically different, the age at diagnosis
and the Z scores of height and weight were higher in the
E60X/DF508 group than among the DF508 homozygotes.
However, the mean BMI was significantly higher ( p=0.05).
The age distribution of the CF patients compound hetero-
zygous for the E60X is also different from that of the DF508
homozygotes present in the French CF Registry, 67% being
15 years old and over compared to 40%. Statistically, no
distinction can be made between the W846X/DF508
compound heterozygotes and the DF508 homozygotes
except for a higher risk of diarrhoea at the time of diagnosis
( p=0.02). However, again, a higher proportion of com-
pound heterozygotes reached young adulthood and adult-
hood (70% being 15 years old and over).
Usually nonsense mutations lead to a severe disease,
when associated with DF508 [12,24]. In the present study,
patients carrying a stop mutation, either E60X or W846X,
associated with DF508 have higher age at diagnosis, higher
anthropometric and pulmonary function parameters, the
mean BMI values being within the normal brackets. The
studied populations are also older (20.6 and 23.5 years old,
respectively), whereas it is close to 12.5 years for the DI507/
DF508, 4005+1G-NA/DF508 or 1078delT/DF508 patients.
Hubert et al. [13] found that some CF adults with DF508
and a nonsense mutation had a severe pancreatic insuffi-
ciency but a milder pulmonary disease. They hypothesized
that the truncated protein can have a residual function, or
that an mRNA splicing can produce a little quantity of
protein in some tissues, which would decrease the pheno-
typic consequences of the mutation.
Five 1078delT/DF508 patients, compared to one among
DF508 homozygotes, had meconium ileus, a borderline
significant result. The 1078delT/DF508 genotype was also
associated with an increased frequency of cirrhosis (6 versus
1, p=0.041). The hypothesis of a link with an increased rate
of meconium ileus is possible. Indeed, De Braekeleer et al.
[25] postulated a possible correlation between meconium
ileus and a higher risk of later complications, whereas
Wilschanski et al. [26] observed an increased risk of liver
disease following meconium ileus.
A previously published study reported the comparison of
CF patients bearing at least one 1078delT mutation with
DF508 homozygotes. Moullier et al. [27] observed that the
CF patients bearing the 1078delT allele had a reduced risk
of meconium ileus and P. aeruginosa colonisation. All were
pancreatic-insufficient, and their pulmonary status was
better. The authors concluded that there was no significant
difference between both groups regarding the pancreatic
status and the pulmonary function, even if the patients
compound heterozygotes for the 1078delT mutation had a
lower predisposition to P. aeruginosa colonisation. Diver-
gences between our results and those of Moullier et al. [27]
can be explained by the structure of the studied populations.
Indeed, they studied all patients bearing the 1078delT allele
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same care unit without matching on age and sex.
In conclusion, western France appears to have a specific
distribution of some CF mutations. Furthermore, disparities
are found regarding the mutation repartition (DI507 in
Normandy, 1078delT, 4005+1G-NA and W846X in western
Brittany). This heterogeneity could be the result of founder
effects and local history and demography. Genotype–
phenotype correlations showed a wide heterogeneity.
Although variations are found, DI507/DF508, 4005+1G-
NA/DF508 and 1078delT/DF508 patients appear to have a
similar disease as the DF508/DF508 patients. CF patients
carrying the E60X or W846X allele have better anthro-
pometric and lung functional results combined with a higher
probability of reaching adulthood. This leads us to conclude
that, although the W846X or E60X mutations should be
considered as severe alleles as regards to pancreatic
function, they are associated with less severe pulmonary
manifestations and, probably, better prognosis. The knowl-
edge of the distribution of uncommon CF mutations specific
to particular areas and of their associated phenotype makes
up an essential tool in the management of local CF patients.Acknowledgments
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